Research
P
reparation of parenteral doses of medications from small volumes using commercially available syringes is imprecise and may result in serious dosing errors. [1] [2] [3] Previously, we showed that 60% of 116 doses prepared from 0.06 mL of stock solution had a dosing error of more than 10%, and 27% had a two-fold dosing error. 2 We hypothesized that small volumes of commercially available formulations are often required to prepare intravenous doses for infants and children.
Methods
We performed two studies: a theoretical study in which we evaluated the potential requirements for small volumes based on recommended use, and a clinical study in which we evaluated actual use. We included medications that had a commercially available parenteral or oral liquid formulation and were in our hospital's formulary. 4, 5 We identified the least concentrated formulation in the product monograph in the 2006 edition of the Canadian Compendium of Pharmaceuticals and Specialties. 5 The primary outcome was the volume of the least concentrated commercially available formulation required to prepare the specified dose. Volumes of less than 0.1 mL were identified.
In the theoretical study of recommended use, we identified the listed clinical reason (indication) to prescribe each eligible drug in the hospital's formulary. 4 We then noted the lowest rec- ) and a 20-kg child 3 years of age (0.464 m 2 ). All of the patients had normal renal and hepatic function.
In the clinical study of actual use, we identified single-injection intravenous medications ordered by physicians that had been administered to children in a university-affiliated pediatric intensive care unit (ICU) in 2006. The volume required to prepare the dose was calculated. If a dose could not be determined and the administered volume was documented, we included this volume in our analysis.
The study design was approved by the Research Ethics Board of the Hospital for Sick Children.
Results
In the theoretical study of the hypothetical patients, we evaluated 59 medications for the neonate and 121 medications for the other pediatric patients (Table 1 ). There were 982 indications listed in the formulary; for 79 (8.0%) of these indications, the recommended dose re quired less than 0.1 mL of stock solution. The number of medications with one or more indications that required less than 0.1 mL stock solution was 13 (22.0%) for the neonate, 20 (16.5%) for the 5-kg child, 12 (9.9%) for
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In our evaluation of oral formulations, there were 845 indications in the formulary; for 9 (1.1%) of these indications, the recommended dose required preparation from less than 0.1 mL. There were seven medications with one or more indications that required preparation from less than 0.1 mL.
In the clinical study of actual use, there were 71 218 (81.8%) intravenous doses administered to 1531 patients admitted to the ICU in 2006. The median volume of stock solution was 1.0 (interquartile range [IQR] 0.3-3.48) mL. Of the doses, 5245 (7.4%) required preparation from less than 0.1 mL of stock solution; 12 439 (17.5%) required preparation from less than 0.2 mL.
For 437 (28.5%) of the ICU admissions, at least one dose was prepared from a volume of less than 0.1 mL. The median number of doses prepared from less than 0.1 mL per admission was 3 (IQR 1-11); in each of 19 admissions, more than 50 administered doses were prepared from less than 0.1 mL. The medications most commonly prepared from less than 0.1 mL were lorazepam, hydrocortisone, ranitidine, methylprednisolone, fentanyl and morphine (Table 2 ).
Interpretation
Our findings indicate a substantial source of dosing error that involved potent medications and affected more than a quarter of the children studied. Small volumes of stock solution are required because of the relatively low doses needed for infants and young children and the relatively high concentrations of commercially available stock solutions. The clinical sequelae of errors occurring as a result of preparing doses from small volumes will be compounded by incomplete safety data, [6] [7] [8] [9] [10] errors in medication orders, 11 and errors in preparation 2,12-14 or administration. 15, 16 Preparation-associated errors could be prevented if more accurate equipment were available to measure small volumes. They could also be avoided with predilution of commercially available solutions, either by means of a doubledilution technique for single doses or the creation of local "stock solutions" for multiple patients. However, additional manipulation of stock solutions may result in further dose-volume inaccuracies.
Our evaluation has four main limitations. First, we assumed that the least concentrated formulation was used. Twenty-five medications had two or more formulations. If the most concentrated formulation of these medications were used, 8715 (12.2%) doses would have been prepared from less than 0.1 mL. Second, we assumed that there was no intermediate dilution. This may have permitted larger volumes of commercially available solution to be used. Third, we assumed that the electronically signed documentation correctly reported the administered dose, which may not have been the case.
14 Fourth, adverse events are challenging to study retrospectively and were not evaluated in our study. 17 The potential clinical implications of errors associated with medications prepared from small volumes are substantial and in excess of the errors in medication orders previously de scribed. 11, 18 The medications most commonly prepared from small volumes in our study included potent narcotics, sedatives and im munosupressants. Re-evaluation of preparation methods, regulatory requirements and manufacturing practices is warranted.
